Ascendis Pharma A/S (ASND)
236.87
-2.17
(-0.91%)
USD |
NASDAQ |
Sep 18, 16:00
236.87
0.00 (0.00%)
After-Hours: 20:00
Ascendis Pharma Free Cash Flow : 388.83M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 388.83M |
| March 31, 2026 | 50.57M |
| December 31, 2025 | 52.82M |
| September 30, 2025 | -115.22M |
| June 30, 2025 | -178.65M |
| March 31, 2025 | -230.25M |
| December 31, 2024 | -324.91M |
| September 30, 2024 | -278.01M |
| June 30, 2024 | -354.18M |
| March 31, 2024 | -456.10M |
| December 31, 2023 | -504.56M |
| September 30, 2023 | -608.86M |
| June 30, 2023 | -571.32M |
| March 31, 2023 | -540.12M |
| December 31, 2022 | -532.20M |
| September 30, 2022 | -535.48M |
| June 30, 2022 | -563.81M |
| March 31, 2022 | -570.07M |
| December 31, 2021 | -522.86M |
| September 30, 2021 | -488.11M |
| June 30, 2021 | -432.88M |
| March 31, 2021 | -357.58M |
| December 31, 2020 | -334.13M |
| September 30, 2020 | -277.36M |
| June 30, 2020 | -272.23M |
| Date | Value |
|---|---|
| March 31, 2020 | -210.82M |
| December 31, 2019 | -202.69M |
| September 30, 2019 | -189.64M |
| June 30, 2019 | -176.85M |
| March 31, 2019 | -194.53M |
| December 31, 2018 | -167.60M |
| September 30, 2018 | -154.68M |
| June 30, 2018 | -128.83M |
| March 31, 2018 | -130.71M |
| December 31, 2017 | -108.39M |
| September 30, 2017 | -97.49M |
| June 30, 2017 | -85.08M |
| March 31, 2017 | -74.15M |
| December 31, 2016 | -67.75M |
| September 30, 2016 | -60.54M |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | -24.95M |
| September 30, 2014 | -19.76M |
| June 30, 2014 | -1.366M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| BioMarin Pharmaceutical, Inc. | 725.08M |
| Novo Nordisk A/S | 7.517B |
| Evaxion AS | -- |
| Genmab A/S | 869.04M |
| Zealand Pharma A/S | -253.76M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 327.52M |
| Cash from Investing (Quarterly) | -3.268M |
| Cash from Financing (Quarterly) | -53.34M |
| Free Cash Flow Per Share (Quarterly) | 4.740 |
| Free Cash Flow to Equity (Quarterly) | 842.38M |
| Free Cash Flow to Firm (Quarterly) | 338.61M |
| Free Cash Flow Yield | 2.58% |